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SARS-CoV-2 Delta (B.1.617.2) variant of concern
(VOC) and other VOCs are spreading in Europe.
Micro-neutralisation assays with sera obtained after
Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in
36 healthcare workers (31 female) demonstrated significant fold change reduction in neutralising titres
compared with the original virus: Gamma (P.1) 2.3,
Beta (B.1.351) 10.4, Delta 2.1 and 2.6. The reduction of
the Alpha (B.1.1.7) variant was not significant. Despite
being lower, remaining neutralisation capacity conferred by Comirnaty against Delta and other VOCs is
probably protective.
Since its emergence, severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) has been responsible for
more than 170 million cases and 3.5 million deaths.
During December 2020 the Comirnaty (BNT162b2
mRNA, BioNTech-Pfizer, Mainz, Germany/New York,
United States (US)) vaccine was approved by the US
Food and Drug Administration and shown to be 95%
efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19) [1]. Clinical and real-world data
demonstrated 95% effectiveness of the mRNA- based
vaccine against the original SARS-CoV-2 and the Alpha
(B.1.1.7) variant [1-3].
Since December 2020, several SARS-CoV-2 variants
have emerged and were classified by the World Health
Organization (WHO) as variants of concern (VOC): Alpha
(Phylogenetic Assignment of Named Global Outbreak
(Pango) lineage designation B.1.1.7), first detected
in the United Kingdom (UK) [4], Beta (B.1.351) first
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documented in South Africa [5] and Gamma (P.1) initially detected in Brazil [6]. Most recently, in April 2021,
the Delta (B.1.617.2) variant was identified in India and
classified on May 11 as VOC due to its fast spread and
potential immune escape [7]. Here, we describe the
neutralising response of sera from healthcare workers
without prior SARS-CoV-2 infection following a second
vaccine dose against viral isolates of the Delta VOC,
and compared it to the response against isolates of the
original, the Alpha, Beta and Gamma VOCs.

Whole genome sequencing

Following importation of SARS-CoV-2 variants by
returning travellers, a national surveillance system has
been set up in Israel, to sequence whole genomes of
SARS-CoV-2-positive samples, to identify circulating
and imported variants. In this analysis, we used the
following isolates: the original (sub-lineage B.1 (hCoV19/Israel/CVL-45526-ngs/2020), Alpha (hCoV-19/Israel/
CVL-46879-ngs/2020), Beta (hCoV-19/Israel/CVL-2557ngs/2020), and Delta sample 1 (S1, hCoV-19/Israel/
CVL-12804/2021) and sample 2 (S2, hCoV-19/Israel/
CVL-12806/2021).
Libraries are prepared using COVID-seq library preparation kit, as per manufacturer’s instructions (Illumina,
Cambridge, UK). Library validation and mean fragment size is determined by TapeStation 4200 via
DNA HS D1000 kit (Agilent Technologies, Santa Clara,
United States) and libraries are pooled, denatured and
diluted to 10pM and sequenced on NovaSeq (Illumina).
Sequences were mapped to the SARS-CoV-2 reference
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Figure 1
Phylogenetic tree of SARS-CoV-2 VOC Delta isolates
originating in India

Testing neutralisation capacity of variants
of concern using SARS-CoV-2 microneutralisation assay

Neutralising antibodies against all VOCs were tested
in serum samples obtained from healthy health care
workers (HCW) of Sheba Medical Center 1 month following the receipt of the second Comirnaty vaccine
dose. Because of limited availability of sera to test all
isolates, samples from two different cohorts originating from the same study were tested. The first cohort
consisted of 19 HCW (17 women and 2 men, median age
48, interquartile range (IQR) 18) and their sera were
tested against the original B.1 virus and the two Delta
VOC isolates. The second cohort was composed of 15
HCW (12 women and 3 men, median age 46, IQR 15) and
their sera were tested against the original virus, as well
as the Alpha, Beta and Gamma VOC.
SARS-CoV-2: severe acute respiratory syndrome coronavirus-2,
VOC: variant of concern.
B.1.617 and B.1.618 (non-VOC) lineages, and their background
lineage B.1 (original virus) were constructed using Nextstrain’s
Augur pipeline and visualised with Auspice [9]. The two SARSCoV-2 VOC Delta isolates, S1 and S2, marked with a black circle,
are located in different branches of the B.1.617.2 lineage.

genomes (NC_045512.2) with Burrows-Wheeler aligner
(BWA) mem [8]. Identification of the variants were done
with Pangolin COVID-19 lineage assigner (https://pangolin.cog-uk.io/) and specific mutations were identified with a custom python code and Nextclade (https://
clades.nextstrain.org/).
The two Delta VOC isolates, which differed by few
mutations (S1. Amino acid substitutions of the Delta
isolates), were further analysed together with additional global sequences downloaded from the Global
initiative on sharing all influenza data (GISAID) hCoV19 database identified as belonging to several main
variants originating in India – Delta, Kappa (B.1.617.1),
as well as the non-VOC B.1.617.3 and B.1.618, and their
background lineage B.1 (S2. GISAID accession numbers
of global variant sequences included in the phylogenetic tree). Phylogenetic trees were constructed using
the Augur pipeline [9] (Figure 1).

Following titration of the original and VOCs, 100 median
tissue culture infectious dose (TCID)50 of SARS-CoV-2
isolates were incubated with inactivated serum samples diluted 1:8 to 1:16,384 in 96 well plates for 60
min at 33 °C. Virus-serum mixtures were added to the
VERO-E6 cells and incubated for 5 days at 33 °C after
which Gentain violet staining (1%) was used to stain
and fix the cell culture layer. Neutralising dilution of
each serum sample was determined by identifying the
well with the highest serum dilution without observable cytopathic effect. A dilution equal to 1:10 or above
was considered neutralising [10].
Serum samples neutralised the original, Delta-S1 and
Delta-S2 virus isolates with geometric mean titres
(GMT) of 247, 107 and 123, respectively (Figure 2a),
demonstrating a twofold reduction in neutralising titres
compared with the original virus in vaccinated individuals. Statistical analysis was performed with the use
of the Wilcoxon matched-pairs signed-rank test. The
statistical significance of the differences between GMT
in the original virus neutralisation assay and Delta-S1
and Delta-S2 neutralisation assays was p < 0.0001 for
both isolates.

All VOCs, were isolated from 300 µl of nasopharyngeal
samples by incubation with confluent VERO-E6 cells for
1 hour at 33 °C followed by addition of 5 ml 2% Fetal
bovine serum (FCS) Minimum Essential Medium (MEM)Eagle medium. The Gamma isolate was kindly provided
by the Tropical Medicine Institute, Sao Paulo University
(Brazil) [6]. Confirmation of VOC identities was established by sequencing of all isolated variants.

Neutralising titres against the original virus, and the
Alpha, Gamma and Beta VOCs were GMT 294, 194, 147
and 33.5, respectively (Figure 2b). Overall, the following fold change reduction in neutralising titres were
observed compared with the original virus: Alpha
1.7 (95% confidence interval (CI): 1.2–2.1), Gamma
2.3 (95% CI: 1.6–3), Beta 10.4 (95% CI: 6.4–14.4),
Delta-S1 2.6 (95% CI: 1.8–3.5) and Delta-S2 2.1 (95%
CI: 1.7–2.5) (Figure 3). Wilcoxon matched-pairs signedrank test demonstrated significant differences in neutralising titres between the original virus and Beta
(p < 0.0001), Gamma (p = 0.002) and both Delta VOC
isolates (p < 0.0001) but not with the Alpha VOC.

Ethical statement

Discussion and Conclusion

Viral isolation of variants of concern

The protocols (numbers: SMC-8008-20, SMC-7875-20)
were approved by the Institutional review board of the
Sheba Medical Center.
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Available data suggest that vaccination with Comirnaty
is effective against the Alpha, Beta and Gamma VOCs,
albeit at different degrees [10-12]. The presence of
www.eurosurveillance.org

Figure 2
Neutralisation titres of individuals vaccinated with a second dose of Comirnatya against SARS-CoV-2 variants of concern
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mutations such as L452R and P681R in the SARS-CoV-2
spike protein’s receptor binding domain of the Delta
variant, shown to be associated with high transmissibility [13] in addition to the fast spread and surge of
severe cases of this variant in the Indian sub-continent
in recent months, raised concern regarding the impact
of this variant and its ability to evade SARS-CoV-2
vaccines [14]. We demonstrate here that neutralising
levels against both Delta isolates were significantly
reduced, although only by twofold compared with the
original virus. Indeed, a recent study similarly showed
that the Delta VOC is reduced by 2.5 folds compared
to a Wuhan-related SARS-CoV-2 strain in individuals
4 to 14 days following the second dose of Comirnaty
[15]. While only a 1.7-fold reduction was observed for
the Alpha VOC compared with the original virus, our
results show a 10-fold reduction in neutralising titres
against the Beta VOC and twofold reduction against
the Gamma VOC. Indeed, a recent study showed that
neutralising titres against both the Beta and Gamma
VOCs are reduced by eight to 12-fold and fourfold,
respectively [11,16,17]. Interestingly, effectiveness of
the Comirnaty vaccine was recently shown to be 75%
against any documented infection with the Beta variant
and 97.4% against severe, critical, or fatal disease [18].
Since reduction in neutralising levels against the Delta
was significantly less than the Beta variant, these data
suggest that Comirnaty vaccination is most probably,
protective against the Delta VOC.

vaccine against known VOCs and highlight the importance of vaccination specifically in areas with high proportion of VOC circulation Strengths of this study are
the use of wild type isolated viruses and not mutated
pseudo-viruses to evaluate the full neutralizing
response and assessing neutralisation of two different
and phylogenetically distinct Delta isolates. Limitations
of the study include the small number of sera analysed, the strong over representation of women (31 of
36 participants) and the lack of T-cell response evaluation. In this study we assessed the neutralising capacity of sera from the vaccinated HCW against the Delta
and not Kappa VOC. The Kappa VOC also originated in
India where it has been circulating since October 2020,
albeit Delta is the dominant sub-lineage circulating.
Overall our results suggest that despite somewhat
reduced neutralisation capacity, Comirnaty vaccination
induces a substantial antibody response also for the
Delta VOC. Further studies are necessary to confirm the
vaccine effectiveness in broader population groups.

The data presented here contribute to the growing evidence of effectiveness of the mRNA-based Comirnaty
www.eurosurveillance.org
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Figure 3
Fold change reduction compared to the original B.1 nonVOC SARS-CoV-2 in neutralising activity of VOCs
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